Literature DB >> 9499769

Vascular endothelial growth factor upregulation in human central retinal vein occlusion.

J Pe'er1, R Folberg, A Itin, H Gnessin, I Hemo, E Keshet.   

Abstract

BACKGROUND AND
OBJECTIVE: Vascular endothelial growth factor (VEGF), a key mediator of intraocular neovascularization, is triggered by hypoxia and has been shown in the eyes of animal models of central retinal vein occlusion (CRVO). However, there is little information on CRVO in humans, in particular, the identity of VEGF-producing cells. STUDY
DESIGN: The study design was molecular localization of the site of VEGF production in the eyes of patients with CRVO. PARTICIPANTS: Ten formaldehyde solution-fixed and paraffin-embedded eyes removed surgically from patients with CRVO and neovascular glaucoma were studied. Five eyes with uveal melanoma and no neovascularization served as control specimens.
METHODS: Thin whole-eye sections were hybridized in situ with a VEGF-specific probe to identify cells producing VEGF messenger RNA (mRNA).
RESULTS: All ten eyes with CRVO showed evidence of intraretinal expression of VEGF mRNA. In all eyes, the inner nuclear layer showed VEGF-upregulated expression. Upregulation of VEGF mRNA was identified in four eyes in the ganglion cell layer and in two eyes with retinal detachment in the outer nuclear layer as well.
CONCLUSIONS: The population of VEGF-producing retinal cells in each eye is likely to represent cells residing in ischemic regions of the retina. Hypoxia-induced VEGF is, most likely, the linking factor between retinal ischemia and iris and retinal neovascularization in CRVO.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9499769     DOI: 10.1016/S0161-6420(98)93020-2

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  58 in total

Review 1.  Anti-vascular endothelial growth factor for macular edema secondary to central retinal vein occlusion.

Authors:  Tasanee Braithwaite; Afshan A Nanji; Paul B Greenberg
Journal:  Cochrane Database Syst Rev       Date:  2010-10-06

2.  Recurrence of macular edema in eyes with branch retinal vein occlusion changes the diameter of unaffected retinal vessels.

Authors:  Jong Chan Im; Jae Pil Shin; In Taek Kim; Dong Ho Park
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2015-09-18       Impact factor: 3.117

Review 3.  Neovascular glaucoma.

Authors:  Sohan Singh Hayreh
Journal:  Prog Retin Eye Res       Date:  2007-08-08       Impact factor: 21.198

4.  Role of vascular endothelial growth factor in the breakdown of the blood-aqueous barrier after retinal laser photocoagulation in pigmented rabbits.

Authors:  Muh-Shy Chen; Ching-Chung Chang; Chang-Ping Lin; Peng-Chen Wang; Li-Rong Lin; Ping-Kang Hou; Tzyy-Chang Ho
Journal:  J Ocul Pharmacol Ther       Date:  2011-10-19       Impact factor: 2.671

5.  A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 5.

Authors:  Michael S Ip; Ingrid U Scott; Paul C VanVeldhuisen; Neal L Oden; Barbara A Blodi; Marian Fisher; Lawrence J Singerman; Michael Tolentino; Clement K Chan; Victor H Gonzalez
Journal:  Arch Ophthalmol       Date:  2009-09

6.  [Cytokine determination from vitreous samples in retinal vascular diseases].

Authors:  M Pfister; F H Koch; J Cinatl; F Rothweiler; R Schubert; P Singh; H Ackermann; M J Koss
Journal:  Ophthalmologe       Date:  2013-08       Impact factor: 1.059

7.  Comprehensive analysis of inflammatory immune mediators in vitreoretinal diseases.

Authors:  Takeru Yoshimura; Koh-hei Sonoda; Mika Sugahara; Yasutaka Mochizuki; Hiroshi Enaida; Yuji Oshima; Akifumi Ueno; Yasuaki Hata; Hiroki Yoshida; Tatsuro Ishibashi
Journal:  PLoS One       Date:  2009-12-04       Impact factor: 3.240

8.  Role of pegaptanib sodium in the treatment of neovascular age-related macular degeneration.

Authors:  Sobha Sivaprasad
Journal:  Clin Ophthalmol       Date:  2008-06

9.  Predictive factors for changes in macular edema in intravitreal bevacizumab therapy of retinal vein occlusion.

Authors:  Thomas Ach; Alexandra E Hoeh; Karen B Schaal; Alexander F Scheuerle; Stefan Dithmar
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2009-09-09       Impact factor: 3.117

10.  Intravitreal bevacizumab in the treatment of neovascular glaucoma secondary to central retinal vein occlusion: a case report.

Authors:  Tarek Alasil; Michael E Rauser
Journal:  Cases J       Date:  2009-10-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.